Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual MeetingPRNewsWire • 06/10/21
Why Is Ionis Pharmaceuticals (IONS) Down 7% Since Last Earnings Report?Zacks Investment Research • 06/04/21
Ionis announces changes to its board of directors at annual meeting of stockholdersPRNewsWire • 06/02/21
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/21
Ionis reports first quarter 2021 financial results and recent business achievementsPRNewsWire • 05/05/21
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander diseasePRNewsWire • 04/20/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONSPRNewsWire • 04/06/21
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALSPRNewsWire • 04/05/21
Ionis Pharma's Ligand-Conjugated Antisense Hits Primary Endpoint Goal In Hereditary Angioedema StudyBenzinga • 03/29/21
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedemaPRNewsWire • 03/29/21